论文部分内容阅读
近10余年来,慢性重症肝炎(下简称慢重肝)的治疗有了一定的改观,病死率已降至60～80%,但血清胆红素(SB)>342umol/L者预后较差,>513umol/L者无存活者。为进一步提高疗效、改善预后、我院自1990年5月～1991年1月,探索酚妥拉明联合强力宁治疗慢重肝14例,效果较好,现小结如下。临床资料一、病例选择:所有病例均符合1990年第六次全国病毒性肝炎学术会议制定的慢重肝诊断标准。SB均>342umol/L。二、一般资料:本组病例均系男性患者,年龄28～70岁,平均55岁。所有病例均有明显的消化道症状及凝血酶原时间(正常值12s)均延长3s以上,其中6例延长达正常值的一倍以上。肝促凝血活酶(HPT.正
In the recent 10 years, the treatment of chronic severe hepatitis has undergone some improvement, the mortality rate has dropped to 60-80%, but the serum bilirubin (SB)> 342umol / L has a poor prognosis, > 513umol / L no survivors. In order to further improve the curative effect and improve the prognosis, our hospital from May 1990 to January 1991, to explore phentolamine combined with powerful Ning in the treatment of 14 cases of chronic severe hepatitis, the effect is better, are summarized as follows. Clinical data A case selection: All cases are in line with the sixth National Conference of Hepatology in 1990 to develop a diagnostic criteria for chronic severe hepatitis. SB are> 342umol / L. Second, the general information: This group of patients were male patients, aged 28 to 70 years, mean 55 years. All cases had obvious gastrointestinal symptoms and prothrombin time (normal 12s) were extended 3s or more, of which 6 cases extended up to more than double the normal value. Hepatic thromboplastin (HPT